IRIS
CHIMENTI, MARIA SOLE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 41.751
AS - Asia 8.066
EU - Europa 5.450
SA - Sud America 995
AF - Africa 145
OC - Oceania 98
Continente sconosciuto - Info sul continente non disponibili 4
Totale 56.509
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 41.472
SG - Singapore 3.604
CN - Cina 1.680
IT - Italia 1.037
RU - Federazione Russa 938
HK - Hong Kong 900
BR - Brasile 827
DE - Germania 590
VN - Vietnam 566
FR - Francia 557
IE - Irlanda 498
UA - Ucraina 415
BD - Bangladesh 356
FI - Finlandia 337
GB - Regno Unito 331
JP - Giappone 248
SE - Svezia 171
CA - Canada 157
PL - Polonia 154
KR - Corea 126
IN - India 124
NL - Olanda 107
ID - Indonesia 73
AR - Argentina 66
MX - Messico 59
ES - Italia 56
AU - Australia 55
BE - Belgio 51
ZA - Sudafrica 51
AT - Austria 50
TR - Turchia 49
NZ - Nuova Zelanda 43
TW - Taiwan 43
DK - Danimarca 39
UZ - Uzbekistan 37
IQ - Iraq 35
EG - Egitto 32
EC - Ecuador 30
IR - Iran 29
PK - Pakistan 28
SA - Arabia Saudita 23
AE - Emirati Arabi Uniti 19
CO - Colombia 19
MY - Malesia 19
PH - Filippine 18
CH - Svizzera 15
IL - Israele 14
JM - Giamaica 14
MA - Marocco 14
RO - Romania 14
GR - Grecia 13
LT - Lituania 13
CL - Cile 12
TH - Thailandia 12
LV - Lettonia 11
VE - Venezuela 11
PE - Perù 10
NP - Nepal 9
PY - Paraguay 9
TN - Tunisia 9
AZ - Azerbaigian 8
BG - Bulgaria 8
ET - Etiopia 8
KG - Kirghizistan 8
HR - Croazia 7
HU - Ungheria 7
KE - Kenya 7
SV - El Salvador 7
TT - Trinidad e Tobago 7
DO - Repubblica Dominicana 6
HN - Honduras 6
NI - Nicaragua 6
SI - Slovenia 6
CR - Costa Rica 5
KH - Cambogia 5
OM - Oman 5
AL - Albania 4
BO - Bolivia 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
GT - Guatemala 4
JO - Giordania 4
KW - Kuwait 4
KZ - Kazakistan 4
NG - Nigeria 4
UY - Uruguay 4
BA - Bosnia-Erzegovina 3
EU - Europa 3
LB - Libano 3
PA - Panama 3
SN - Senegal 3
YE - Yemen 3
BF - Burkina Faso 2
BH - Bahrain 2
BS - Bahamas 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
LK - Sri Lanka 2
MK - Macedonia 2
NO - Norvegia 2
Totale 56.479
Salva come PNG Salva come JPEG
Città #
Wilmington 10.067
Woodbridge 9.293
Houston 9.136
Singapore 1.896
Fairfield 1.283
Ashburn 1.025
Ann Arbor 982
Hong Kong 886
San Jose 860
Chandler 799
Seattle 523
Beijing 456
Dallas 450
Cambridge 438
Dublin 424
New York 408
Jacksonville 335
Medford 328
Santa Clara 312
Columbus 297
The Dalles 291
Los Angeles 288
Council Bluffs 281
Rome 231
Helsinki 216
Ho Chi Minh City 204
Tokyo 195
Zhengzhou 159
Moscow 155
Lawrence 153
Lauterbourg 138
Dearborn 132
Buffalo 115
Hanoi 114
Elk Grove Village 98
São Paulo 95
Kraków 94
Milan 94
San Diego 76
Munich 73
Chicago 71
London 63
Redwood City 63
Menlo Park 59
Redondo Beach 56
Nanjing 53
Nuremberg 51
Orem 51
Seoul 51
Shanghai 50
Toronto 50
Boardman 48
Warsaw 48
Brussels 45
Guangzhou 44
Amsterdam 42
Tauranga 42
Stockholm 40
Frankfurt am Main 39
Jakarta 38
Chaozhou 37
Montreal 37
Shenzhen 36
Copenhagen 35
Denver 35
North Bergen 35
Phoenix 35
Johannesburg 34
Brooklyn 33
Chengdu 33
Atlanta 32
Norwalk 31
Chennai 30
Palo Alto 28
Hefei 26
Lappeenranta 26
Suzhou 26
Mülheim 25
San Francisco 25
Belo Horizonte 24
Melbourne 24
Florence 23
Rio de Janeiro 23
Taipei 23
Da Nang 22
Haiphong 22
Naples 22
Boston 21
Falls Church 21
Manchester 20
Mountain View 20
Philadelphia 20
Vienna 19
Brasília 18
Poplar 18
San Mateo 17
Verona 17
Augusta 16
Bologna 16
Chongqing 16
Totale 45.425
Salva come PNG Salva come JPEG
Nome #
Challenges in the treatment of Rheumatoid Arthritis 856
Type I lamellar ichthyosis improved by tazarotene 0.1% gel 585
Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases 562
Efficacy and safety of infliximab in psoriatic patients over the age of 65 552
Complement, infection, and autoimmunity 547
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis 541
Complement and autoimmunity 530
Synovial fluid from patients with rheumatoid arthritis modulates monocyte cell-surface phenotype 524
Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients 515
Peripheral blood natural killer cells and mild thyroid abnormalities in women with reproductive failure 510
Autoantibodies in inflammatory arthritis 509
Vasculitides and the Complement System: a Comprehensive Review 503
C3 come indicatore di efficacia terapeutica in pazienti con artrite reumatoide in terapia con inibitori del TNFα 498
Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: Is it possible after disease remission? 487
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 482
Apremilast for the treatment of psoriasis. 477
Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab 475
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 473
Expression of immunoglobulin-like transcript 4 as an inhibitory receptor in patients with psoriatic arthritis 472
Evidence of IL-17 producing innate lymphoid cells in peripheral blood from patients with enteropathic spondyloarthritis 470
Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor 469
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response 463
Role of the complement system in rheumatoid arthritis and psoriatic arthritis: Relationship with anti-TNF inhibitors 462
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 460
Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review 457
Complement system in rheumatoid arthritis: evidence of correlation with disease activity but not with anti-citrullinated protein antibodies 456
Profile of certolizumab and its potential in the treatment of psoriatic arthritis 456
Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients 456
Self-reported adherence to a home-based exercise program among patients affected by psoriatic arthritis with minimal disease activity 456
Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. 450
The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies 450
Sistema complementare e artrite reumatoide: Correlazioni con autoanticorpi, caratteristiche cliniche e di laboratorio e farmaci anti-TNF α 449
Two HLA-B27 alleles differently associated with spondylarthritis, B*2709 and B*2705, display similar intracellular trafficking and oligomer formation 448
Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: A systematic review 448
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis 448
IL-21 in the pathogenesis and treatment of skin diseases 445
Role of IL-23 in the pathogenesis of psoriasis: A novel potential therapeutic target? 444
Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: The experience of two Italian integrated Dermatology/Rheumatology outpatient clinics 439
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study 439
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 438
Occurrence of localized scleroderma morphea in a patient with rheumatoid arthritis treated with etanercept 437
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 437
Diagnosis of pigmented skin lesions by dermoscopy: web-based training improves diagnostic performance of non-experts 436
The significance of the development of antinuclear antibodies during infliximab treatment 433
The autoimmune side of hereditary angioedema: Insights on the pathogenesis 432
Auto-reactions, autoimmunity and psoriatic arthritis 432
Alteration of antigen-independent immunologic synapse formation between dendritic cells from HLA-B27-transgenic rats and CD4+ T cells: selective impairment of costimulatory molecule engagement by mature HLA-B27 431
Metabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab 431
A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors 427
Small-medium vessel vasculitides: Is the complement system a potential forgotten target? 424
Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept 422
Complement system in psoriatic arthritis: a useful marker and a potential therapeutic target of anti-tnf-alpha treatment 421
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis 420
Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways 417
S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis 417
Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis 415
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers 414
Nintedanib in Rheumatoid Arthritis–Related Interstitial Lung Disease: Real-World Safety Profile and Risk of Side Effects and Discontinuation 412
Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment 412
The interplay between inflammation and metabolism in rheumatoid arthritis 412
Insights on the role of physical activity in patients with rheumatoid arthritis 411
Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse 410
Discontinuation of anti-TNFα therapy due to remission in rheumatoid arthritis: A retrospective study 410
Skin reaction associated with chrysotherapy: an unusual case 403
Innate Immune System at the Maternal–Fetal Interface: Mechanisms of Disease and Targets of Therapy in Pregnancy Syndromes 398
The significance the role of anti-tnf-alpha effects on endothelial dysfunction in psoriasic arthritis 391
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Design, development, and use in therapy 388
Small molecule therapy for managing moderate to severe psoriatic arthritis 383
The pathogenic role of the complement system in rheumatoid arthritis and its relationship with TNFα inhibitors 382
Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate 382
Ultrasound assessment of enthesis thickness in psoriasis and psoriatic arthritis: A cross-sectional study 381
Morphometric analysis of capillaroscopic images during psoriatic arthritis: comparison with rheumatoid artrhitis 379
Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab 376
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 372
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 370
From patients’ needs to treatment outcomes in psoriasis: Results from the ‘pSORRIDI’ experience 370
Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence 369
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy 367
Histopathology of the skin in rheumatic diseases 366
Natural killer and b cells in patients with rheumatoid arthritis and psoriatic arthritis treated with etanercept 365
The complex interplay between rheumatoid arthritis and atopy: Focus on anti-TNFα treatment 361
Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: New biomarkers in PsA 360
Systemic sclerosis: Exploring the potential interplay between thyroid disorders and pregnancy outcome in an Italian cohort 358
Tofacitinib for the treatment of moderate-to-severe psoriasis 356
How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography 352
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 346
High-dose Intravenous Immunoglobulin for Severe Drug Reactions: Efficacy in Toxic Epidermal Necrolysis 343
Hereditary angioedema and autoimmunity 343
Treatment of Hailey-Hailey disease with topical calcitriol 342
Effects of abatacept on T-lymphocyte sub-populations and immunoglobulins in patients affected by rheumatoid arthritis 342
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 342
Factors predicting 2 years of remission and low disease activity in rheumatoid arthritis patients treated with TNF-inhibitors 340
Evidence for the detection of subclinical retinal involvement in systemic Lupus erythematosus and Sjögren syndrome: a potential association with therapies 318
Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. 316
Radiologically significant joint improvement in a patient affected by psoriatic arthritis treated with adalimumab 315
Interaction between microbiome and host genetics in psoriatic arthritis 300
Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress 298
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 284
Use of synthetic and biological DMARDs in patients with enteropathic spondyloarthritis: a combined gastro-rheumatological approach 273
Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view 255
Totale 42.300
Salva come PNG Salva come JPEG
Categoria #
all - tutte 151.829
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 151.829
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.702 95 197 160 89 50 86 86 87 93 122 173 464
2022/20232.026 207 176 88 255 188 450 163 135 182 41 103 38
2023/20241.061 95 30 36 28 131 266 43 137 58 19 53 165
2024/20255.419 182 1.196 625 307 71 404 281 214 405 449 698 587
2025/202611.857 690 1.096 1.264 1.187 1.075 415 1.275 1.269 1.134 1.027 834 591
2026/2027144 144 0 0 0 0 0 0 0 0 0 0 0
Totale 57.554